Market Cap 509.76B
Revenue (ttm) 88.82B
Net Income (ttm) 14.07B
EPS (ttm) N/A
PE Ratio 20.23
Forward PE 19.33
Profit Margin 15.84%
Debt to Equity Ratio 0.50
Volume 8,466,900
Avg Vol 8,664,178
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 93%
Beta 0.36
Analysts Strong Sell
Price Target $207.88

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
3DBuilds
3DBuilds Dec. 16 at 1:58 PM
0 · Reply
UIS299010
UIS299010 Dec. 16 at 1:01 PM
$TTD $VRT $JNJ $CLS Still manually filtering targets? Why not click to see our curated list of key industries!
0 · Reply
Quantumup
Quantumup Dec. 16 at 12:14 PM
Wedbush Added $TYRA to their Best Idea List while⬆️the PT to $37 from $30 and reiterating at an Outperform rating. $URGN $JNJ $BBIO $ASND SNY BMRN Wedbush said—We are adding TYRA to the Wedbush Best Ideas List ahead of a busy 2026, with data from two ongoing Ph 2 studies in intermediate-grade non-muscle invasive bladder cancer (IR-NMIBC) (1H:26) and in achondroplasia (ACH) (2H:26). TYRA also recently announced plans to initiate a Ph 2 study in upper tract urothelial carcinoma (UTUC) in 2026, which we believe is an underappreciated opportunity and a potential fast-to-market strategy. We are increasing our price target to $37 (from $30) as we realign our model away from the metastatic UC setting to UTUC, and update timelines based on recent guidance.
0 · Reply
FrankieSmilez
FrankieSmilez Dec. 16 at 11:56 AM
$PFE $NVAX $MRNA $JNJ Pfizer forecasts lower-than-expected profits for 2026
0 · Reply
shadowpawn
shadowpawn Dec. 16 at 2:16 AM
0 · Reply
FrankieSmilez
FrankieSmilez Dec. 16 at 1:36 AM
$PFE $NVAX $MRNA $JNJ Pfizer is sharing their guidance tomorrow, and I'm not really sure what to expect. Covid sales have declined, and their recent acquisitions are still getting started before they make it to market. I have a hunch it might turn into a "sell the news" scenario, regardless of whether the news is positive or negative, especially since the stock is hovering around its peak at 26.50. But if the news is bad, it could really hit the entire Covid health sector hard.
2 · Reply
stockanalysis_
stockanalysis_ Dec. 15 at 9:14 PM
S&P 500 - 1D Performance: $NVDA $AMZN $AVGO $LLY $JNJ Market Heatmap: https://stockanalysis.com/markets/heatmap/?ref=saveontrading
0 · Reply
ceinos
ceinos Dec. 15 at 8:04 PM
$JNJ 190
0 · Reply
TraderFlorida
TraderFlorida Dec. 15 at 6:39 PM
$JNJ - up $41.00 from suggested buy entry. Projected price target $217.00 area. Congrat's!
0 · Reply
Trader_Ty
Trader_Ty Dec. 15 at 5:43 PM
$JNJ monster
1 · Reply
Latest News on JNJ
2 Recession-Proof Stocks to Watch in December

Dec 16, 2025, 8:05 AM EST - 2 hours ago

2 Recession-Proof Stocks to Watch in December

WMT


Final Trade: JNJ, NVO, UBER, BMY

Dec 15, 2025, 6:22 PM EST - 16 hours ago

Final Trade: JNJ, NVO, UBER, BMY

BMY NVO UBER


Johnson & Johnson: Reliable Cash Flows, Moderate Expectations

Dec 11, 2025, 7:05 PM EST - 4 days ago

Johnson & Johnson: Reliable Cash Flows, Moderate Expectations


16 Quality Stocks to Own for a Volatile Market

Dec 1, 2025, 1:23 PM EST - 14 days ago

16 Quality Stocks to Own for a Volatile Market

CSCO LLY XOM


2 Top Dividend Stocks to Buy and Hold

Nov 30, 2025, 4:05 AM EST - 16 days ago

2 Top Dividend Stocks to Buy and Hold

BMY


Best Dividend Aristocrats For December 2025

Nov 29, 2025, 8:02 AM EST - 17 days ago

Best Dividend Aristocrats For December 2025

ABBV ABT ADM ADP AFL ALB AMCR


Dogs Of The Dow Continue Outperforming Broader Market

Nov 29, 2025, 1:45 AM EST - 17 days ago

Dogs Of The Dow Continue Outperforming Broader Market

AMGN DIA MAGS SPY


Wasatch Global Value Fund Q3 2025 Performance Review

Nov 28, 2025, 7:50 AM EST - 18 days ago

Wasatch Global Value Fund Q3 2025 Performance Review

BABA CNC DOX NVDA


3 Superb Dividend Stocks to Hold for the Next 20 Years

Nov 27, 2025, 6:30 AM EST - 19 days ago

3 Superb Dividend Stocks to Hold for the Next 20 Years

KO O


1 Reason Why Shares of Johnson & Johnson Are Surging This Month

Nov 21, 2025, 12:43 PM EST - 24 days ago

1 Reason Why Shares of Johnson & Johnson Are Surging This Month


Why Johnson & Johnson's Share Price Is Popping This Month

Nov 19, 2025, 12:24 PM EST - 26 days ago

Why Johnson & Johnson's Share Price Is Popping This Month


Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion

Nov 17, 2025, 8:29 AM EST - 4 weeks ago

Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion


Halda Therapeutics Announces Acquisition by Johnson & Johnson

Nov 17, 2025, 8:15 AM EST - 4 weeks ago

Halda Therapeutics Announces Acquisition by Johnson & Johnson


Bristol Myers, J&J halt heart drug trial after interim review

Nov 14, 2025, 8:03 AM EST - 4 weeks ago

Bristol Myers, J&J halt heart drug trial after interim review

BMY


2 Strong Healthcare Stock Picks for Dividend Investors

Nov 13, 2025, 3:55 AM EST - 4 weeks ago

2 Strong Healthcare Stock Picks for Dividend Investors

ABBV


Johnson & Johnson: Dividends Don't Lie

Nov 7, 2025, 5:40 AM EST - 5 weeks ago

Johnson & Johnson: Dividends Don't Lie


3DBuilds
3DBuilds Dec. 16 at 1:58 PM
0 · Reply
UIS299010
UIS299010 Dec. 16 at 1:01 PM
$TTD $VRT $JNJ $CLS Still manually filtering targets? Why not click to see our curated list of key industries!
0 · Reply
Quantumup
Quantumup Dec. 16 at 12:14 PM
Wedbush Added $TYRA to their Best Idea List while⬆️the PT to $37 from $30 and reiterating at an Outperform rating. $URGN $JNJ $BBIO $ASND SNY BMRN Wedbush said—We are adding TYRA to the Wedbush Best Ideas List ahead of a busy 2026, with data from two ongoing Ph 2 studies in intermediate-grade non-muscle invasive bladder cancer (IR-NMIBC) (1H:26) and in achondroplasia (ACH) (2H:26). TYRA also recently announced plans to initiate a Ph 2 study in upper tract urothelial carcinoma (UTUC) in 2026, which we believe is an underappreciated opportunity and a potential fast-to-market strategy. We are increasing our price target to $37 (from $30) as we realign our model away from the metastatic UC setting to UTUC, and update timelines based on recent guidance.
0 · Reply
FrankieSmilez
FrankieSmilez Dec. 16 at 11:56 AM
$PFE $NVAX $MRNA $JNJ Pfizer forecasts lower-than-expected profits for 2026
0 · Reply
shadowpawn
shadowpawn Dec. 16 at 2:16 AM
0 · Reply
FrankieSmilez
FrankieSmilez Dec. 16 at 1:36 AM
$PFE $NVAX $MRNA $JNJ Pfizer is sharing their guidance tomorrow, and I'm not really sure what to expect. Covid sales have declined, and their recent acquisitions are still getting started before they make it to market. I have a hunch it might turn into a "sell the news" scenario, regardless of whether the news is positive or negative, especially since the stock is hovering around its peak at 26.50. But if the news is bad, it could really hit the entire Covid health sector hard.
2 · Reply
stockanalysis_
stockanalysis_ Dec. 15 at 9:14 PM
S&P 500 - 1D Performance: $NVDA $AMZN $AVGO $LLY $JNJ Market Heatmap: https://stockanalysis.com/markets/heatmap/?ref=saveontrading
0 · Reply
ceinos
ceinos Dec. 15 at 8:04 PM
$JNJ 190
0 · Reply
TraderFlorida
TraderFlorida Dec. 15 at 6:39 PM
$JNJ - up $41.00 from suggested buy entry. Projected price target $217.00 area. Congrat's!
0 · Reply
Trader_Ty
Trader_Ty Dec. 15 at 5:43 PM
$JNJ monster
1 · Reply
ajmore
ajmore Dec. 15 at 5:06 PM
$PFE could, just could pfizer be on $MRK or $JNJ shopping menu! interesting activity and compliments offerings.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 15 at 4:41 PM
0 · Reply
ZacksResearch
ZacksResearch Dec. 15 at 4:06 PM
FDA greenlight just widened the runway for $JNJ 🚀 The FDA approved Akeega for expanded use into earlier-stage prostate cancer, supported by strong phase III data and a first-of-its-kind precision combo — a meaningful expansion of its treatment footprint. See why this approval matters for JNJ’s growth story 👉 https://www.zacks.com/stock/news/2804520/fda-approves-jjs-akeega-for-expanded-use-in-prostate-cancer?cid=sm-stocktwits-2-2804520-teaser-24841&ADID=SYND_STOCKTWITS_TWEET_2_2804520_TEASER_24841
0 · Reply
LimitTorch_1680
LimitTorch_1680 Dec. 15 at 4:05 PM
$JNJ mega-cap pharma, steady dividend trend, plays well when risk appetite cools
0 · Reply
TwongStocks
TwongStocks Dec. 15 at 3:16 PM
$JNJ Receives a National Priroity Review voucher for teclistamab in combination with daratumumab to treat relapsed/refractory multiple myeloma. https://www.fda.gov/news-events/press-announcements/fda-proactively-awards-national-priority-voucher-based-strong-phase-3-study-results
0 · Reply
ZacksResearch
ZacksResearch Dec. 15 at 3:06 PM
$JNJ expands precision therapy approval — a game-changer for prostate cancer? 🚀 The FDA greenlit Johnson & Johnson's Akeega for a new prostate cancer indication, marking the first precision medicine combo of a PARP inhibitor with an androgen receptor pathway inhibitor for BRCA2m mCSPC. This approval follows phase III data showing a 54% risk reduction in radiographic progression or death. Discover how this could impact JNJ's ambitious $50B oncology sales goal by the end of this decade 👉 https://www.zacks.com/stock/news/2804520/fda-approves-jjs-akeega-for-expanded-use-in-prostate-cancer?cid=sm-stocktwits-2-2804520-body-24839&ADID=SYND_STOCKTWITS_TWEET_2_2804520_BODY_24839
0 · Reply
Deeznutsswapmeet
Deeznutsswapmeet Dec. 15 at 2:54 PM
$JNJ $KVUE Wrong again and again and again and again…
0 · Reply
3DBuilds
3DBuilds Dec. 15 at 1:43 PM
0 · Reply
JarvisFlow
JarvisFlow Dec. 15 at 1:24 PM
B of A Securities has updated their rating for Johnson & Johnson ( $JNJ ) to Neutral with a price target of 220.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 15 at 10:33 AM
$JNJ RSI: 68.43, MACD: 4.0324 Vol: 4.12, MA20: 203.67, MA50: 194.81 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 5:34 AM
Actionable Trade Alert for $JNJ: Market Context: $JNJ is currently trading at $211.58, showing strong momentum with an RSI of 66.67, indicating it is nearing overbought territory. The recent price action is above both the 30-day MA (199.19) and 50-day MA (195.71), suggesting bullish sentiment. The 60-day high of $212.27 is just above the current price, which may act as a resistance level. Directional Bias: Given the RSI and the proximity to the 60D high, we expect a potential pullback or consolidation before further upward movement. However, the overall trend remains bullish. Trade Plan: - Suggested Entry: $211.60 - Stop Loss: $204.00 (approximately 3.5% below entry) - Take Profit Targets: 1. $215.00 (1.14% ROI) 2. $218.00 (3.15% ROI) 3. $220.00 (4.01% ROI) To achieve at least a 17% ROI, consider leveraging options or increasing position size strategically. Monitor price action closely around the 60D high. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
RockyTSTH
RockyTSTH Dec. 15 at 4:15 AM
OPTION WATCHLIST 12/14/2025 $JPM - Stock in a strong uptrend and close to all time highs. Looking for calls above $320 for a move towards $330 and higher. Stock is decent at indicator level. $JNJ - Stock having a flag breakout on the daily time frame as stock makes all time highs. Looking for calls as long as $210 holds for a move towards $225 and higher. $BAC -St Another bank stock make new highs on the daily time frame. Stock in a strong uptrend. Looking for calls as long as $55 holds for a move towards $60 and higher. $ORCL - Stock testing recent lows at $185 but holding strong. Looking for puts here if that level breaks. Stock does have an earnings gap to fill to the upside. Calls above $200 look good as well. Below $185 we can see retest of $165 $MCD - Stock near all time highs making an ascending triangle pattern on the daily. Looking for breakout moves over $320 for a move towards $335 and higher. Stock is decent at indicator level.
0 · Reply